Paladin Labs to buy struggling Labopharm in $20M deal
This article was originally published in Scrip
Executive Summary
Paladin Labs, one of Canada's leading specialty pharma companies, has agreed to buy struggling Labopharm, a firm based in Laval, Quebec, for approximately C$20 million, 3-4 times the potential revenues of Labopharm’s product, tramadol. Labopharm focuses on new controlled-release formulations of painkillers and other products but has faced setbacks over the past few years, leading it to shrink its workforce and seek strategic alternatives.